Pornlada Likasitwatanakul

Pornlada Likasitwatanakul

Auto-generated profile, based on publicly available information

Pornlada Likasitwatanakul

Department of Medicine, University of Minnesota-Twin Cities , Minneapolis, MN 55455

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
SSSandor Spisak
Sandor Spisak
DCDavid Chen
David Chen
PLPornlada Likasitwatanakul
Pornlada Likasitwatanakul
PDPaul Doan
Paul Doan
ZLZhixin Li
Zhixin Li
NSNilay Sethi
Nilay Sethi
Aberrant stem cell-like activity and impaired differentiation are central to the development of colorectal cancer (CRC). To identify functional mediators of these key cellular programs, we engineer a dual endogenous reporter system by genome-editing the SOX9 and KRT20 loci of human CRC cell lines to express fluorescent reporters, broadcasting aberrant stem cell-like and differentiation activity, respectively. By applying a CRISPR screen targeting 78 epigenetic regulators with 542 sgRNAs to this platform, we identify factors that contribute to stem cell-like activity and differentiation in CRC. Perturbation single cell RNA sequencing (Perturb-seq) of validated hits nominate SMARCB1 of the BAF complex (also known as SWI/SNF) as a negative regulator of differentiation across an array of neoplastic colon models. SMARCB1 is a dependency and required for in vivo growth of human CRC models. These studies highlight the utility of biologically designed endogenous reporter platforms to uncover regulators with therapeutic potential.

2 January 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
JHJustin Hwang
Justin Hwang
PLPornlada Likasitwatanakul
Pornlada Likasitwatanakul
SDSachin Kumar Deshmukh
Sachin Kumar Deshmukh
SWSharon Wu
Sharon Wu
JKJason J. Kwon
Jason J. Kwon
Emmanuel S. AntonarakisEmmanuel S. Antonarakis
Emmanuel S. Antonarakis
Purpose: Around 10% to 15% of prostate cancers harbor recurrent aberrations in the Forkhead Box A1 gene, FOXA1, whereby the alteration type and the effect on the forkhead (FKH) domain affect protein function. We developed a FOXA1 classification system to inform clinical management. Experimental Design: A total of 5,014 prostate cancer samples were examined using whole-exome and -transcriptome sequencing from the Caris Life Sciences database. We denoted class 1 FOXA1 alterations as missense and in-frame insertions/deletions with subclasses oriented with respect to the FKH domain. These were in the first part of the FKH domain [class 1A: amino acids (AA) 168–246], within the Wing2 region of FKH (class 1B: AA 247–269), or outside FKH (class 1C: AA 1–167, 270+). Two hotspot missense mutations at R219 were denoted class 2. Class 3 included predicted truncating mutations with subclasses partitioned based on the FKH domain (class 3A: AA 1–269 and class 3B: AA 270+). Class 4 represented FOXA1 amplifications. Real-world overall survival and therapy outcomes were determined from insurance claims. Results: FOXA1 alterations did not influence survival when considered in aggregate but had distinct prognostic effects when stratified by class. In primary prostate samples, class 1A alterations were associated with overall improved survival (HR, 0.57; P = 0.03); a similar trend was seen in metastatic biopsies with class 1B (HR, 0.84; P = 0.09). Conversely, in primary specimens, class 1C exhibited worse survival upon second-generation androgen receptor signaling inhibitor treatment (HR, 1.93; P < 0.001). Class 2 mutations (R219C/S) were enriched in neuroendocrine prostate cancers and were associated with overall poor survival (HR, 2.05; P < 0.001) and worse outcomes to first-line androgen-deprivation therapies (HR, 2.5; P < 0.001). Class 3A alterations indicated improved survival (HR, 0.70; P = 0.01), whereas class 3B alterations portended poor outcomes (HR, 1.50; P < 0.001). Amplifications (class 4) indicated poor outcomes in metastatic samples (HR, 1.48; P = 0.02). Molecularly, different FOXA1 alteration classes harbored distinct mutational and immunologic features as well as unique transcriptional programs. Finally, relative to European Americans, African Americans had increased class 1C alterations, whereas Asian/Pacific Islander patients had increased class 1B alterations. Conclusions: FOXA1 alterations should not be interpreted in aggregate, as different classes are associated with divergent molecular features and clinical outcomes. Our revised classification schema facilitates clinical decision-making for patients with prostate cancer and uncovers important racial differences.

10 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
PLPornlada Likasitwatanakul
Pornlada Likasitwatanakul
ZLZhixin Li
Zhixin Li
PDPaul Doan
Paul Doan
SSSandor Spisak
Sandor Spisak
ARAkhouri Kishore Raghawan
Akhouri Kishore Raghawan
NSNilay Sethi
Nilay Sethi
Dysregulated epigenetic programs that restrict differentiation, reactivate fetal genes, and confer phenotypic plasticity are critical to colorectal cancer (CRC) development. By screening a small molecule library targeting epigenetic regulators using our dual reporter system, we found that inhibiting histone deacetylase (HDAC) 1/2 promotes CRC differentiation and anti-tumor activity. Comprehensive biochemical, chemical, and genetic experiments revealed that on-target blockade of the HDAC1/2 catalytic domain mediated the differentiated phenotype. Unbiased profiling of histone posttranslational modifications induced by HDAC1/2 inhibition nominated acetylation of specific histone lysine residues as potential regulators of differentiation. Genome-wide assessment of implicated marks indicated that H3K27ac gains at HDAC1/2-bound regions associated with open chromatin and upregulation of differentiation genes upon HDAC1/2 inhibition. Disrupting H3K27ac by degrading acetyltransferase EP300 rescued HDAC1/2 inhibitor-mediated differentiation of a patient-derived CRC model using single cell RNA-sequencing. Genetic screens revealed that DAPK3 contributes to CRC differentiation induced by HDAC1/2 inhibition. These results highlight the importance of specific chemically targetable histone modifications in governing cancer cell states and epigenetic reprogramming as a therapeutic strategy in CRC. BRIEF SUMMARY HDAC1/2 inhibition promotes colorectal cancer differentiation via gains in H3K27ac, which can be reversed by blocking its acetyltransferase EP300.

4 March 2026 in The Oncologist
Verified
Journal Article
Open access
PLPornlada Likasitwatanakul
Pornlada Likasitwatanakul
SBSteven M Blinka
Steven M Blinka
JZJabra Zarka
Jabra Zarka
GGGeorges Gebrael
Georges Gebrael
EWEmily Weg
Emily Weg
Emmanuel S. AntonarakisEmmanuel S. Antonarakis
Emmanuel S. Antonarakis
Background: Clival metastases are a rare and clinically aggressive manifestation of advanced prostate cancer, associated with cranial nerve palsy and poor survival. The molecular features of prostate cancers giving rise to clivus metastases remain unknown. Patients and methods: We performed a multi-center retrospective study across six institutions, identifying prostate cancer patients with radiographically confirmed clival metastases and available next-generation sequencing (NGS) data. Baseline characteristics and clinical outcomes were collected. Genomic alterations from tissue- and/or blood-based assays were aggregated at the patient level and compared with a publicly available metastatic castration-resistant prostate cancer (mCRPC) cohort (SU2C/PCF). Results: Fifty-nine patients with clival metastases contributed 87 molecular assays. More than half of patients had Gleason grade group 5 cancer and presented with de novo metastatic (M1) disease. The median interval from initial prostate cancer diagnosis to clival metastasis was 71.4 months (95% CI, 42.0-101.7), while median overall survival following clival involvement was only 15.3 months (95% CI, 6.9-22.8). Compared with the SU2C/PCF mCRPC cohort, clival metastases showed significant enrichment of BRAF and CHEK2 alterations as well as homologous recombination repair (HRR) with relative depletion of AR-related, PI3K pathway, and G2–M pathway alterations. Conclusion: Prostate cancers giving rise to clival metastases exhibit a distinct molecular profile enriched for DNA damage–repair and RAF kinase alterations, suggesting unique metastatic biology and potential therapeutic vulnerabilities.

3 March 2025
Verified
Other
Open access
JHJustin Hwang
Justin Hwang
PLPornlada Likasitwatanakul
Pornlada Likasitwatanakul
SDSachin Kumar Deshmukh
Sachin Kumar Deshmukh
SWSharon Wu
Sharon Wu
JKJason J. Kwon
Jason J. Kwon
Emmanuel S. AntonarakisEmmanuel S. Antonarakis
Emmanuel S. Antonarakis
Supplementary Table 1-11 from Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes

3 March 2025
Verified
Other
Open access
JHJustin Hwang
Justin Hwang
PLPornlada Likasitwatanakul
Pornlada Likasitwatanakul
SDSachin Kumar Deshmukh
Sachin Kumar Deshmukh
SWSharon Wu
Sharon Wu
JKJason J. Kwon
Jason J. Kwon
Emmanuel S. AntonarakisEmmanuel S. Antonarakis
Emmanuel S. Antonarakis
OS based on FOXA1 alteration class. OS is depicted based on forest plots as organized by each FOXA1 alteration class for (A) all prostate tumors, (B) prostate samples, and (C) metastatic samples. D, Kaplan–Meier curves for different alterations classes compared with WT. E, Outcomes for class 2 are compared with all other alteration classes.